Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1132403

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	265417
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265418 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	298 label Biography information for Steve McCabe

1132404

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	265418
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265417 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	298 label Biography information for Steve McCabe

1132424

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of cases of melanoma.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	265456
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>On 16 June 2014, a local pilot campaign launched in Devon, Cornwall and Somerset to raise awareness of the signs of skin cancer. It encouraged people to tell their doctor if they noticed any unusual or persistent changes to their skin. It ran until 27 July 2014 and included adverts in the press and on local radio, as well as some direct mail to the target group.</p><p> </p><p>Skin Cancer awareness month is an annual awareness campaign that takes place every May. The campaign aims to raise awareness of the dangers of unprotected sun exposure and educate the public about the ways to help prevent skin cancer.</p><p>The Sunbeds (Regulation) Act 2010 came into force in April 2011 in England and Wales to prohibit under-18s from using sunbeds.</p><p> </p><p>Public Health England (PHE) contributed to the revision of the World Health Organization publication “Artificial tanning devices - Public health interventions to manage sunbeds”, which was published in 2017. PHE advises that sunbeds emit ultraviolet radiation, which can cause tanning and sunburn.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 20/06/2019 14:14:40 answering member 4455 label Biography information for Seema Kennedy
tabling member	1409 label Biography information for Mr Gregory Campbell

1132427

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genomics: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many patients have received whole genome sequencing through the NHS; and how many of those patients had a type of blood cancer.
tabling member constituency	Totnes
tabling member printed	Dr Sarah Wollaston
uin	265508
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.</p><p>During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:</p><p>- Seriously ill children likely to have a rare genetic disorder;</p><p>- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and Acute Myeloid Leukaemia.</p><p> </p><p>As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 265509 265510 question first answered 20/06/2019 15:34:08 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4073 label Biography information for Dr Sarah Wollaston

1132428

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genomics: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many patients he estimates will benefit from whole genome sequencing in (a) 2019 and (b) each of the next five years.
tabling member constituency	Totnes
tabling member printed	Dr Sarah Wollaston
uin	265509
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.</p><p>During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:</p><p>- Seriously ill children likely to have a rare genetic disorder;</p><p>- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and Acute Myeloid Leukaemia.</p><p> </p><p>As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 265508 265510 question first answered 20/06/2019 15:34:08 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4073 label Biography information for Dr Sarah Wollaston

1132429

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genomics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when the NHS Genomic Medicine Service will begin performing whole genome sequencing.
tabling member constituency	Totnes
tabling member printed	Dr Sarah Wollaston
uin	265510
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.</p><p>During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:</p><p>- Seriously ill children likely to have a rare genetic disorder;</p><p>- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and Acute Myeloid Leukaemia.</p><p> </p><p>As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 265508 265509 question first answered 20/06/2019 15:34:08 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4073 label Biography information for Dr Sarah Wollaston

1132430

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pathology: Vacancies
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the level of vacancy is in histopathology departments.
tabling member constituency	Totnes
tabling member printed	Dr Sarah Wollaston
uin	265511
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS Improvement publishes vacancy data for three staff groups; doctors, nurses and ‘other staff’. These vacancy statistics are published for England and at the regional level of North, Midlands and East, London and South.</p><p>They do not specifically produce vacancy data for histopathology departments or any vacancy data for each National Health Service hospital or trust.</p><p>NHS Digital published the latest NHS Improvement vacancy data which can be found in the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-vacancies-survey/february-2015---march-2019-provisional-experimental-statistics" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-vacancies-survey/february-2015---march-2019-provisional-experimental-statistics</a></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 20/06/2019 13:12:02 answering member 1585 label Biography information for Stephen Hammond
tabling member	4073 label Biography information for Dr Sarah Wollaston

1132431

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy Integration Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the current balance of the pharmacy integration fund is; and what initiatives have been supported by that fund since its inception.
tabling member constituency	Rother Valley
tabling member printed	Sir Kevin Barron
uin	265429
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England and NHS Improvement are awaiting the completion of the annual audit of its accounts, therefore no final figure is currently available for the balance of the Pharmacy Integration Fund (PhIF). The PhIF has supported a range of initiatives, including:</p><p>- Recruitment and training of pharmacists to support integrated urgent care services, offering patients and care staff direct access to clinical advice and care from pharmacists;</p><p>- Putting pharmacists and pharmacy technicians into the multi-disciplinary teams delivering enhanced health in care homes, to support medicines optimisation for people who live in care homes;</p><p>- The development of an urgent medicines supply service. This connects people who contact NHS 111 for urgent access to medicines with local community pharmacies who are able to dispense, and redirects demand out of general practitioner out of hours services, and/or accident and emergency departments;</p><p>- The piloting of a minor illness service, which enables people who contact NHS 111 to get urgent care and advice from a local community pharmacy for a range of common illness complaints; and</p><p>- Providing leadership training for the profession to support them to work effectively with their partners in the emerging integrated care systems, with a focus on delivering the range of benefits of medicines optimisation.</p><p>Further information can be found on NHS England’s website and accessed via the following link:</p><p><a href="https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-integration-fund/" target="_blank">https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-integration-fund/</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 20/06/2019 14:13:14 answering member 4455 label Biography information for Seema Kennedy
tabling member	392 label Biography information for Sir Kevin Barron

1132444

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Steroid Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he has taken to ensure continuity of supply for steroid treatments in the event that the UK leaves the EU without a deal.
tabling member constituency	Luton South
tabling member printed	Mr Gavin Shuker
uin	265503
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The Government remains committed to leaving the European Union with a deal. However, as a responsible Government, we will continue to prepare to minimise any disruption to the supply of medicines and medical products in a potential ‘no deal’ scenario.</p><p>The Government fully understands that maintaining access to steroid treatments is vitally important to many people in this country. We are continuing to work with trade bodies and other stakeholders to carefully review the implications of the extension to the Article 50 period until 31 October at the latest, before sharing further guidance with industry at the earliest opportunity.</p><p> </p><p>On 26 April we wrote to suppliers advising that, until further guidance is provided, all no-deal measures (such as stockpiles, additional buffer stocks, etc) should remain in place but on hold.</p><p> </p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 20/06/2019 09:28:01 answering member 1585 label Biography information for Stephen Hammond
tabling member	4013 label Biography information for Mr Gavin Shuker

1132453

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Arthritis: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to (a) ensure patient safety and (b) support pioneering medical research to tackle (i) rheumatoid arthritis and (ii) other inflammatory conditions in the event that the UK leaves the EU without a deal.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	265579
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The Government remains committed to leaving the European Union with a deal. However, as a responsible Government, we must plan for every eventuality, including no deal.</p><p>We have been working closely with partners across the health and care system and industry to ensure the continued health and safety of patients, including ensuring supplies of medicines and medical products, and securing the future of our EU health and care workforce.</p><p>The Department has published EU Exit operational readiness guidance for the health and care system in England outlining actions that providers and commissioners of health and social care services should take to prepare for, and manage, the risks of a no deal exit scenario.</p><p>We continue to monitor and analyse overall staffing levels across the National Health Service and adult social care, and we are working across Government to ensure there will continue to be sufficient staff to deliver the high-quality services on which the public relies following the UK’s exit from the EU.</p><p>The UK has an outstanding track record for research into rheumatoid arthritis and other inflammatory conditions. The Government invests over £1 billion in health research through the National Institute for Health Research (NIHR). This provides direct funding for health research and clinical trials and also the skills, facilities and infrastructure to undertake clinical trials in the health and care service funded by public, charity and industry funders.</p><p>In 2017/18, the NIHR provided £11.7 million funding for research on the inflammatory and immune system (this includes rheumatoid arthritis, connective tissue diseases, autoimmune diseases, allergies and normal development and function of the immune system, as per the UK Clinical Research Collaboration Health Research Classification System, of which £1.2 million was for research on rheumatoid arthritis. In addition, the NIHR Clinical Research Network provides the support to deliver research by public, charity and industry funders in the health and care system.</p><p>The UK and the EU have a long record of jointly tackling global challenges, with strong existing links already in place between our research and innovation communities, and we want to continue this important collaboration in science, research and innovation, including in pioneering medical research for rheumatoid arthritis and other inflammatory conditions.</p><p>As a responsible Government, we are continuing to prepare for all scenarios. In the event that the UK leaves the EU without a deal at the end of this extension period, the Government has confirmed that the funding commitments made under the guarantee and the extension still stand. Through these commitments, the Government will underwrite funding for all successful competitive eligible UK bids to Horizon 2020 that are submitted before the end of the Programme. This guarantee will apply for the lifetime of projects and will provide funding for UK participation in pioneering Horizon 2020 medical research projects can continue.</p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 20/06/2019 15:36:21 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4488 label Biography information for Martyn Day